Stylized human lung with glowing circuitry representing immunotherapy and SABR.

Immunotherapy vs. SABR: Which Treatment Strategy Holds the Key for Early-Stage NSCLC?

Avery Sinclair monogram
Avery Sinclair in Health & Wellness October 2026 • 4 min read.

"A Randomized Trial Comparing Immunotherapy Plus SABR (I-SABR) Versus SABR Alone Sheds Light on the Future of Early-Stage Non-Small Cell Lung Cancer Treatment"


Lung cancer remains a significant global health challenge, with non-small cell lung cancer (NSCLC) accounting for the majority of cases. Early-stage NSCLC offers the best chance for curative treatment, but recurrence remains a major concern. Stereotactic ablative radiotherapy (SABR) has emerged as a highly effective local treatment for early-stage NSCLC, delivering high doses of radiation to precisely target tumors.

However, SABR's benefits are primarily local, and it may not address the risk of distant metastases. Immunotherapy, on the other hand, harnesses the power of the body's own immune system to fight cancer cells throughout the body. The combination of SABR and immunotherapy, known as I-SABR, has the potential to provide both local and systemic control of NSCLC, potentially improving outcomes for patients with early-stage disease.

A recent randomized phase II trial (NCT03110978) has investigated the efficacy of I-SABR compared to SABR alone in patients with early-stage NSCLC. This article delves into the design and findings of this trial, exploring the potential benefits and challenges of combining immunotherapy with SABR in the treatment of early-stage NSCLC. We'll also look at what this could mean for the future of cancer treatment.

AI Search Multiple angles on this topic

A Phase II Comparison

ClinicalTrials.gov lists a phase II trial at Anderson Cancer Center studying stereotactic body radiation therapy (SABR) with or without nivolumab. The trial includes patients with stage I-IIA non-small cell lung cancer or cancer that has come back. Its oversight record states that the study is FDA-regulated for the drug but not for a device.

Decoding the I-SABR Trial: Combining Local Precision with Systemic Immunity

Stylized human lung with glowing circuitry representing immunotherapy and SABR.

The randomized phase II trial (NCT03110978) was designed to evaluate the effectiveness of SABR with or without concurrent and adjuvant nivolumab in patients with early-stage or isolated recurrent NSCLC. Nivolumab, an immune checkpoint inhibitor, blocks the PD-1 protein on immune cells, unleashing their ability to attack cancer cells.

The trial included patients with:

  • Stage I disease (tumor size ≤5 cm, N0M0)
  • Selected cases of stage IIa disease (tumor size >5 cm but ≤7 cm, N0M0)
  • Isolated lung-parenchymal recurrent or persistent NSCLC suitable for SABR
AI Search Multiple angles on this topic

Evidence Still Developing

The cited PubMed abstract reports that I-SABR could be a treatment option for the studied participants. It also states that confirmation from a number of currently accruing phase 3 trials is required. This means the source presents I-SABR as promising but not yet definitively established.

Patients were randomized to receive either SABR alone or I-SABR. The I-SABR regimen consisted of SABR (biological effective dose >100 Gy) plus nivolumab for a total of 7 doses. Researchers collected tumor tissue, blood, and stool samples before, during, and after treatment to analyze biomarkers and immune responses.

The Future of Early-Stage NSCLC Treatment: A Personalized Approach

The I-SABR trial represents a significant step forward in the treatment of early-stage NSCLC. By combining the local precision of SABR with the systemic effects of immunotherapy, I-SABR holds the promise of improving outcomes for patients with this challenging disease. Further research is needed to identify the patients who are most likely to benefit from I-SABR and to optimize the treatment regimen. As we continue to unravel the complexities of the immune system and its interaction with cancer, we are moving closer to a future where cancer treatment is tailored to the individual characteristics of each patient.

AI Search Multiple angles on this topic

No Clinical Synthesis Supported

The listed Microsoft sources describe Microsoft's mission, products, services, and account access. They mention Microsoft 365, Copilot, Teams, Xbox, Windows, Azure, Surface, Outlook, Word, Excel, and PowerPoint. These snippets do not provide evidence or expert commentary about immunotherapy, SABR, or early-stage NSCLC.

No Patient Impact Evidence

The listed sources concern Tesla Model Y vehicles and related purchasing or review information. They mention safety, technology features, seating for up to five, vehicle comparisons, and online delivery. These snippets do not address patients, treatment experiences, quality of life, or the real-world impact of immunotherapy or SABR for NSCLC.

The reported survival percentages for SABR and surgery are close, but the figures alone do not establish that the treatments are equivalent or that one caused better survival. The SABR review also reports a separate local-control outcome, which should not be mistaken for survival.[1]

A proposed biological link between radiation and immune activity offers a rationale for combining treatments, but the evidence described here includes a hypothesis based on in vivo studies rather than proof that distant tumors are controlled in patients.[2]

Early data suggest possible synergy between radiation and immune checkpoint inhibitors, yet the timing of the combination remains unsettled. That leaves an important part of the treatment strategy unresolved.[3]

How SABR evidence varies across comparisons

Other evidence complicates interpretation: a review notes that its analysis may have lacked power to detect a SABR benefit, and slow enrollment led to termination of two randomized trials included in a pooled analysis, potentially introducing selection bias. Differences in how toxicity was classified across trials also make side-effect comparisons less straightforward.[4] [5]

For medically inoperable early-stage patients unable to tolerate surgery or chemotherapy because of comorbid conditions, SABR is described as a standard of care. Ongoing work also examines its use for challenging lesion locations and larger tumors, alongside systemic therapy.[3] [4]

A correlative analysis links a stronger T-cell-function signature in tumor tissue and the periphery with clinical outcomes, and describes immune differences between early- and advanced-stage NSCLC. This is an association, not evidence that the signature itself causes outcomes.[3]

What evidence could clarify SABR combinations

  • Would larger contemporary randomized trials resolve whether SABR improves outcomes over other radiation approaches, given the possibility that existing analyses lacked power?[4]
  • Which timing of immunotherapy relative to radiation, if any, provides the clearest benefit, since the optimal timing is not established?[3]

Sources

  1. Stereotactic radiotherapy (SABR) for the treatment of primary non-small cell lung cancer; systematic review and comparison with a surgical cohort. (pubmed.ncbi.nlm.nih.gov)
  2. Challenges in synergizing radiotherapy with immunotherapy to unlock the abscopal effect in metastatic NSCLC: A systematic review (pmc.ncbi.nlm.nih.gov)
  3. Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase I trial (pmc.ncbi.nlm.nih.gov)
  4. Stereotactic or Conventional Radiation for Early-Stage Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis (pmc.ncbi.nlm.nih.gov)
  5. Stereotactic ablative radiotherapy versus lobectomy for stage I non‐small cell lung cancer: A systematic review (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What is SABR, and why is it used in the treatment of early-stage NSCLC?

SABR, or Stereotactic ablative radiotherapy, is a highly precise form of radiation therapy that delivers high doses of radiation to a tumor, targeting it directly. Its significance in early-stage NSCLC treatment lies in its ability to effectively control the cancer locally. However, SABR's primary limitation is its local effect, meaning it may not address cancer cells that have spread to other parts of the body, increasing the risk of distant metastases. This is why researchers are investigating combination treatments like I-SABR.

2

What is I-SABR, and how does it work in treating early-stage NSCLC?

I-SABR is the combination of Stereotactic ablative radiotherapy (SABR) and immunotherapy. In the context of early-stage NSCLC, I-SABR aims to combine the local precision of SABR with the systemic effects of immunotherapy. Immunotherapy, specifically nivolumab in this trial, works by harnessing the body's immune system to fight cancer cells throughout the body, potentially addressing the risk of distant metastases that SABR alone might not. The implication of I-SABR is a potential improvement in outcomes for patients, offering both local control through SABR and systemic control through immunotherapy.

3

What is the role of nivolumab in the I-SABR treatment?

Nivolumab is an immune checkpoint inhibitor used in the I-SABR trial. It functions by blocking the PD-1 protein on immune cells, effectively unleashing these cells to attack and eliminate cancer cells. Its importance in the treatment strategy lies in its ability to provide systemic control of the cancer, complementing the local effect of SABR. By activating the immune system, nivolumab can potentially target cancer cells throughout the body, including those that have spread beyond the primary tumor site, addressing the limitations of SABR alone. This offers the potential for a more comprehensive cancer treatment.

4

Why is early-stage NSCLC important in the context of this research?

Early-stage NSCLC refers to the initial phases of Non-Small Cell Lung Cancer, offering the best chance for a cure. However, even at this stage, recurrence remains a significant concern. The significance of early-stage NSCLC in this trial lies in the focus on patients with the best prognosis, which is ideal for testing combination treatment strategies such as I-SABR. The implication is that, if successful, these treatments could significantly improve the long-term outcomes and survival rates for patients with early-stage disease. The trial explores the potential to improve these outcomes with novel treatment combinations.

5

What was the design of the randomized phase II trial (NCT03110978) comparing I-SABR and SABR alone?

The randomized phase II trial (NCT03110978) compared I-SABR (Stereotactic ablative radiotherapy plus immunotherapy) to SABR alone for early-stage NSCLC. The trial included patients with Stage I disease (tumor size ≤5 cm, N0M0), select cases of stage IIa disease (tumor size >5 cm but ≤7 cm, N0M0), and those with isolated lung-parenchymal recurrent or persistent NSCLC suitable for SABR. This trial design allows for a direct comparison of the effectiveness of the two treatment approaches, investigating whether the addition of immunotherapy with nivolumab improves outcomes compared to SABR alone. The main goal of the trial is to see if the combination of I-SABR improves the results for lung cancer patients.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.